Zentalis Pharmaceuticals, Inc. SEC filings ZNTL
Zentalis Pharmaceuticals, Inc. has 546 filings in SEC EDGAR's recent list, going back to Dec 19, 2017. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 27, 2026 | — |
| 4 | Insider transaction | Oct 1, 2026 | Sep 30, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 19, 2026 | — |
| 4 | Insider transaction | Aug 19, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
| 424B5 | Prospectus supplement | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2026 | — |
| 424B5 | Prospectus supplement | Aug 13, 2026 | — |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 30, 2026 | — |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | May 27, 2026 | May 26, 2026 |
| 3 | Initial insider ownership | May 27, 2026 | May 22, 2026 |
| DEFA14A | Additional proxy material | May 27, 2026 | — |
| 8-K |
Current report
Officer or director change
|
May 27, 2026 | May 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 5, 2026 | May 5, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 16, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 17, 2026 | Apr 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 9, 2026 | Apr 9, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 3, 2026 | — |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 10, 2026 | Feb 6, 2026 |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 8, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 8, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 8, 2026 |
| 4 | Insider transaction | Jan 9, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 9, 2026 | Jan 6, 2026 |
| 4 | Insider transaction | Jan 8, 2026 | Dec 31, 2025 |
| 3 | Initial insider ownership | Jan 8, 2026 | Dec 15, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 5, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jan 2, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 30, 2025 | — |
| 4 | Insider transaction | Dec 15, 2025 | Dec 15, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 15, 2025 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 15, 2025 | Dec 15, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 12, 2025 | — |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 10, 2025 | Nov 10, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 14, 2025 | — |
| 4 | Insider transaction | Oct 1, 2025 | Oct 1, 2025 |
| 3 | Initial insider ownership | Sep 22, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 26, 2025 | Aug 26, 2025 |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2025 | Aug 6, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 16, 2025 | — |
| 4 | Insider transaction | Jun 18, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 18, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 18, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 18, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 18, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 2, 2025 | May 31, 2025 |
| DEFA14A | Additional proxy material | May 23, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 20, 2025 | May 20, 2025 |
| S-8 | Employee stock plan registration | May 14, 2025 | — |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 13, 2025 | — |
| 4 | Insider transaction | Apr 30, 2025 | Apr 30, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 17, 2025 |
| ARS | Annual report to shareholders | Apr 30, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 28, 2025 | Apr 27, 2025 |
| EFFECT | Filing | Apr 4, 2025 | — |
| CORRESP | Letter to the SEC | Apr 2, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 26, 2025 | Mar 26, 2025 |
| S-3 | Shelf registration | Mar 26, 2025 | — |
| 10-K | Annual report | Mar 26, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 17, 2025 | Mar 15, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Feb 12, 2025 | Feb 6, 2025 |
| 144 | Notice of proposed sale | Feb 11, 2025 | — |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 4, 2025 | Jan 31, 2025 |
| 4 | Insider transaction | Feb 4, 2025 | Jan 31, 2025 |
| 4 | Insider transaction | Feb 4, 2025 | Jan 31, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 4, 2025 | — |
| 144 | Notice of proposed sale | Feb 3, 2025 | — |
| 144 | Notice of proposed sale | Feb 3, 2025 | — |
| 144 | Notice of proposed sale | Feb 3, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 31, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 31, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 29, 2025 | Jan 29, 2025 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure, Other events
|
Jan 28, 2025 | Jan 22, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 22, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 8, 2025 | — |
| 4 | Insider transaction | Jan 3, 2025 | Jan 2, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Dec 19, 2024 | Dec 17, 2024 |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 10, 2024 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Dec 6, 2024 | — |
| 4 | Insider transaction | Dec 3, 2024 | Dec 2, 2024 |
| 4 | Insider transaction | Dec 3, 2024 | Dec 2, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 4 | Insider transaction | Nov 13, 2024 | Nov 13, 2024 |
| 3 | Initial insider ownership | Nov 13, 2024 | Nov 13, 2024 |
| 3 | Initial insider ownership | Nov 13, 2024 | Nov 13, 2024 |
| 3 | Initial insider ownership | Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 13, 2024 | Nov 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 12, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 6, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 4, 2024 | — |
| 144 | Notice of proposed sale | Oct 31, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 18, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 17, 2024 | — |
| CORRESP | Letter to the SEC | Oct 10, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 7, 2024 | — |
| 4 | Insider transaction | Oct 4, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 16, 2024 | Sep 16, 2024 |
| UPLOAD | Letter from the SEC | Sep 12, 2024 | — |
| 10-Q | Quarterly report | Aug 9, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2024 | Aug 9, 2024 |
| 4 | Insider transaction | Jun 21, 2024 | Jun 21, 2024 |
| 4 | Insider transaction | Jun 21, 2024 | Jun 21, 2024 |
| 4 | Insider transaction | Jun 21, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 3, 2024 | Jun 3, 2024 |
| 144 | Notice of proposed sale | May 31, 2024 | — |
| 4 | Insider transaction | May 31, 2024 | May 31, 2024 |
| 4 | Insider transaction | May 29, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 29, 2024 | May 24, 2024 |
| DEFA14A | Additional proxy material | May 29, 2024 | — |
| 8-K |
Current report
Officer or director change
|
May 29, 2024 | May 24, 2024 |
| 144 | Notice of proposed sale | May 9, 2024 | — |
| 4 | Insider transaction | May 9, 2024 | May 9, 2024 |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 21, 2024 |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| 3 | Initial insider ownership | Apr 11, 2024 | Apr 5, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 11, 2024 | Apr 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 9, 2024 | Apr 9, 2024 |
| S-8 | Employee stock plan registration | Feb 29, 2024 | — |
| S-3ASR | Automatic shelf registration | Feb 29, 2024 | — |
| 10-K | Annual report | Feb 27, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2024 | Feb 27, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 15, 2024 | Feb 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 13, 2024 | — |
| 144 | Notice of proposed sale | Feb 12, 2024 | — |
| 144 | Notice of proposed sale | Feb 12, 2024 | — |
| 144 | Notice of proposed sale | Feb 12, 2024 | — |
| 4 | Insider transaction | Feb 12, 2024 | Feb 12, 2024 |
| 4 | Insider transaction | Feb 12, 2024 | Feb 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 5, 2024 | Feb 1, 2024 |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| 144 | Notice of proposed sale | Feb 2, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 29, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 25, 2024 | — |
| 8-K |
Current report
Listing notice, Officer or director change, Regulation FD disclosure
|
Jan 25, 2024 | Jan 19, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2024 | Jan 5, 2024 |
| 4 | Insider transaction | Jan 3, 2024 | Jan 2, 2024 |
| 3 | Initial insider ownership | Jan 3, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Dec 21, 2023 | Dec 20, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Dec 11, 2023 | — |
| SC 13G | Ownership over 5% (passive) | Nov 17, 2023 | — |
| 4 | Insider transaction | Nov 13, 2023 | Nov 10, 2023 |
| 4 | Insider transaction | Nov 13, 2023 | Nov 13, 2023 |
| 10-Q | Quarterly report | Nov 6, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 6, 2023 | Nov 6, 2023 |
| SC 13G | Ownership over 5% (passive) | Oct 10, 2023 | — |
| 4 | Insider transaction | Oct 6, 2023 | Oct 4, 2023 |
| 4 | Insider transaction | Oct 6, 2023 | Oct 4, 2023 |
| 4 | Insider transaction | Oct 6, 2023 | Oct 4, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 6, 2023 | Oct 6, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZNTL (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1725160
- Former names
- Zentalis Pharmaceuticals, LLC (until Apr 6, 2020); Zeno Pharma, LLC (until Sep 5, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.